The DOI matches its Crossref record; 202 of the 205 references it cites were found in a registry or an index; 2 of the 287 sources its claims cite were checked for support.
Benzodiazepines in epilepsy: pharmacology and pharmacokinetics
Open accessAbstract
Benzodiazepines (BZDs) remain important agents in the management of epilepsy. They are drugs of first choice for status epilepticus and seizures associated with post-anoxic insult and are also frequently used in the treatment of febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in a variety of clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. Potential shortcomings of BZDs include tolerance, withdrawal symptoms, adverse events, such as cognitive impairment and sedation, and drug interactions. Benzodiazepines differ in their pharmacologic effects and pharmacokinetic profiles, which dictate how the drugs are used. Among the approximately 35 BZDs available, a select few are used for the management of seizures and epilepsy: clobazam, clonazepam, clorazepate, diazepam, lorazepam and midazolam. Among these BZDs, clorazepate has a unique profile that includes a long half-life of its active metabolite and slow onset of tolerance. Additionally, the pharmacokinetic characteristics of clorazepate (particularly the sustained-release formulation) could theoretically help minimize adverse events. However, larger, controlled studies of clorazepate are needed to further examine its role in the treatment of patients with epilepsy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
191 Not checked yet · 37 No basis given · 8 Own interpretation · 8 Own result · 2 Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“they suggested that longer than 6 months may be needed for recovery from some deficits.”
What the sources say
- Supportedcites [170] Barker, 2004, Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis, Arch Clin Neuropsychol source
The Discussion states that the data do not support full cognitive recovery in the first 6 months after cessation and suggests that some deficits may take longer than 6 months to recover. This directly supports the citing sentence’s hedged wording. (LLM, conf=0.95)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite the long half-life of DMD, a missed dayÕs dosing can result in altered peak-to-trough concentration ratios.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, the differences between peak and trough plasma DMD concentrations after a missed daily dose of clorazepate increased more with the immediate-release formulation than with the sustained-release formulation (Table 4).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the effect was modest, the sustained-release tablet maintained higher trough concentrations after a missed daily dose and replacement of the missed dose.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was little difference between the two formulations in peak and trough concentrations following a missed dayÕs dose.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Peak ⁄ trough difference b after missed dose(s) (lg ⁄ ml) | NA | 0.18 | 0.41 | NA | 0.18 | 0.42”
What the sources say
- Not checked yetcites [71] Riss
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Among the approximately 35 BZDs available, a select few are used for the management of seizures and epilepsy: clobazam, clonazepam, clorazepate, diazepam, lorazepam and midazolam.”
- Also stated in: § Introduction · plain
“few of the approximately 35 BZDs available worldwide (2) are used for managing epilepsy.”
What the sources say
- Not checked yetcites [2] International Narcotics Control Board
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
In the paper
“Midazolam is an exception, with low oral bioavailability due to metabolism by cytochrome P-450 (CYP) enzyme 3A5 in intestinal epithelial tissue, which can reduce by up to 50% the fraction of the dose reaching the bloodstream (24).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines have differences in their physiochemical properties, most notably lipid solubility, which influence their rate of absorption and diffusion into tissue compartments and their pharmacokinetics.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The CYP isoenzymes catalyzing these reactions include 3A4, 3A5, 2B6, 2C9 and 2C19 (Tables 2 and 3).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 106
- Probably not a substantial claim. 28
- The quote only partly states this claim. 4
Every source the paper cites for this claim was checked and supports it.
In the paper
“For individuals who use BZDs long term, the possible degree of recovery and the extent of residual impairment that may remain after the drugs are withdrawn are unclear (170).”
What the sources say
- Supportedcites [170] Barker, 2004, Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis, Arch Clin Neuropsychol source
The Abstract explicitly says that the degree of recovery after withdrawal and the level of residual impairment in long-term benzodiazepine users are unclear. It also reports improvement in many cognitive areas but not full recovery within the first six months, consistent with uncertainty about the eventual extent of impairment. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, when a missed dayÕs dose of the sustainedrelease formulation was simulated, peak-to-trough differences increased by 0.01 lg ⁄ ml (5.9%) with no dose replacement and increased by 0.24 lg ⁄ ml (141.2%) with replacement of the missed dose (Table 4).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The time to maximum concentration was 2.43 and 9.20 h for the immediate-release and sustained-release formulations respectively.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When a missed dayÕs dose of the immediate-release formulation was simulated, peak-to-trough differences (compared with steady state) increased by 0.05 lg ⁄ ml (38.5%) with no dose replacement and increased by 0.29 lg ⁄ ml (223.1%) with replacement of the missed doses (Table 4).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean steady-state plasma DMD concentration was approximately 0.71 lg ⁄ ml for the immediaterelease formulation and 0.73 lg ⁄ ml for the sustained-release”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in trough plasma DMD concentrations (%) | NA | )44.1 | )41.9 | NA | )48.8 | )48.8”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Peak ⁄ trough difference b at steady state (lg ⁄ ml) | 0.17 | NA | NA | 0.13 | NA | NA”
What the sources say
- Not checked yetcites [71] Riss
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in peak plasma DMD concentrations (%) | NA | )29.6 | 6.0 | NA | )27.1 | 9.6”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Peak ⁄ trough difference b after missed dose(s) (lg ⁄ ml) | NA | 0.18 | 0.41 | NA | 0.18 | 0.42”
What the sources say
- Not checked yetcites [71] Riss
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in peak plasma DMD concentrations (%) | NA | )29.6 | 6.0 | NA | )27.1 | 9.6”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Change in trough plasma DMD concentrations (%) | NA | )44.1 | )41.9 | NA | )48.8 | )48.8”
What the sources say
- Not checked yetcites [71] Riss
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“are also frequently used in the treatment of febrile, acute repetitive and alcohol withdrawal seizures”
- Also stated in: § Introduction · plain
“Benzodiazepines also continue to play major roles in treating other conditions such as febrile seizures, acute repetitive seizures and alcohol withdrawal seizures.”
What the sources say
- Not checked yetcites [81] Ko, 1997
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · plain
In the paper
“Benzodiazepines are used in a variety of clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes.”
- Also stated in: § Efficacy · plain
“Benzodiazepines are versatile drugs that can be employed in a variety of clinical settings because of their broad spectrum of activity and multiple formulations and because they can be administered by several routes”
What the sources say
- Not checked yetcites [81] Ko, 1997
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Clinical advantages of these drugs include rapid onset of action, high efficacy rates and minimal toxicity.”
- Also stated in: § Introduction · plain
“The major clinical advantages of BZDs are high efficacy rates, rapid onset of action and minimal toxicity.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
- Also stated in: § Introduction · plain
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines (BZDs) remain important agents in the management of epilepsy.They are drugs of first choice for status epilepticus and seizures associated with post-anoxic insult”
- Also stated in: § Introduction · plain
“Nonetheless, benzodiazepines (BZDs), which have been used since the 1960s, remain important in epilepsy management and are the drugs of first choice for status epilepticus and seizures associated with postanoxic insult.”
What the sources say
- Not checked yetcites [77] Alldredge, 2001, A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus, N Engl J Med source
- Not checked yetcites [78] Shaner, 1988, Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin, Neurology source
- Not checked yetcites [79] Treiman, 1998, A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines differ in their pharmacologic effects and pharmacokinetic profiles, which dictate how the drugs are used.”
- Also stated in: § Introduction · hedged
“Thus, pharmacokinetic differences often dictate the use of specific BZDs, route(s) of administration and formulation(s).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · hedged
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Potential shortcomings of BZDs include tolerance, withdrawal symptoms, adverse events, such as cognitive impairment and sedation, and drug interactions.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Clobazam is an exception with its 1-5-BZD structure (17).”
What the sources say
- Not checked yetcites [17] Shorvon, 1995
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“When orally administered, most BZDs are extensively and rapidly absorbed, with bioavailabilities varying from 80% to 100% and times to peak concentration ranging from minutes to several hours (Table 1).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Transmitter-gated chloride channels, GABA C receptors, are selectively activated by certain conformationally restricted GABA analogs and are not modulated by steroids, BZDs or barbiturates (3).”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Benzodiazepines also have large volumes of distribution, are highly bound to plasma proteins (Table 1) and readily cross into the placenta and breast milk (25).”
What the sources say
- Not checked yetcites [25] Hobbs, 1996
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, the pharmacokinetic characteristics of clorazepate (particularly the sustained-release formulation) could theoretically help minimize adverse events.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Diazepam and lorazepam are primarily used for management of seizure emergencies, whereas clobazam, clonazepam and clorazepate are commonly used in chronic epilepsy management.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The inhibitory neurotransmitter GABA binds to the receptor to open the chloride ion gates and produce an inhibitory current (6,8).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Ligand-activated ion channels that are selectively blocked by bicuculline and modulated by steroids, BZDs, and barbiturates are known as GABA A receptors (3).”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Among these BZDs, clorazepate has a unique profile that includes a long half-life of its active metabolite and slow onset of tolerance.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines differ in their rates of elimination and the formation of pharmacologically active metabolites (Table 2).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The basic chemical structure of BZDs is formed from the fusion of a benzene ring and a sevenmembered diazepine ring (16) (Fig. 1).”
What the sources say
- Not checked yetcites [16] Feldman, 1997
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines allosterically bind to the receptor at a different location than GABA does and enhance the chloride channelÕs conductance by increasing the frequency of gated channel opening (6,7,(10)(11)(12).”
What the sources say
- Not checked yetcites [6] Macdonald, 1994, GABAA receptor channels, Annu Rev Neurosci source
- Not checked yetcites [7] McKernan, 1996, Which GABAA-receptor subtypes really occur in the brain?, Trends Neurosci source
- Not checked yetcites [10] Atack, 2006, Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA5-selective compound L-655,708, Drug Metab Dispos source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“There are three principal c-aminobutyric acid (GABA) receptor subtypes.”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The GABA A receptor consists of a pentameric structure with multiple subunits that are necessary for normal physiologic function.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Midazolam often is used as an alternative to diazepam and lorazepam in seizure emergencies and for treating refractory status epilepticus.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Following rapid uptake, BZDs redistribute into less well-perfused tissues; the rate of redistribution is the fastest for the most lipid-soluble drugs (25).”
What the sources say
- Not checked yetcites [25] Hobbs, 1996
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Based on in vivo point mutations, a-1-GABA A receptors have been found to mediate sedation and anterograde amnesia and to partially mediate anticonvulsant activity, whereas a-2-GABA A receptors mediate anxiolysis (14,15).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The second receptor subtype, GABA B , consists of G-protein-coupled, seven-transmembrane receptors, which are selectively activated by (R)-())baclofen and 3-aminopropylphosphinic acid and are blocked by phaclofen (3).”
What the sources say
- Not checked yetcites [3] Chebib, 1999, The ABC of GABA receptors: a brief review, Clin Exp Pharmacol Physiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There are, however, differences among BZDs in affinity for receptor subtypes, which may produce different pharmacologic effects.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines are classified as low, medium (e.g.clorazepate and diazepam) or high (e.g.clonazepam and lorazepam) potency (18,19).”
What the sources say
- Not checked yetcites [18] Nelson, 1999, Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal, Can J Clin Pharmacol
- Not checked yetcites [19] Chouinard, 2004, Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound, J Clin Psychiatry
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The receptor subunits are assembled from combinations of 19 polypeptides (i.e.a1-6, b1-3, c1-3, d, e, p, h and q1-3) (4); different subunit combinations determine the pharmacologic properties of the receptor (5,6).”
What the sources say
- Not checked yetcites [4] Simon, 2004, Analysis of the set of GABAA receptor genes in the human genome, J Biol Chem source
- Not checked yetcites [5] Sieghart, 1999, Structure and subunit composition of GABAA receptors, Neurochem Int source
- Not checked yetcites [6] Macdonald, 1994, GABAA receptor channels, Annu Rev Neurosci source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Benzodiazepines cross the blood-brain barrier rapidly, although the diffusion rate into the brain varies by drug and is largely determined by lipophilicity (21).”
What the sources say
- Not checked yetcites [21] Rey, 1999, Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes, Clin Pharmacokinet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In neonates, the t 1 ⁄ 2 of clorazepate is prolonged and clearance is decreased (67).”
What the sources say
- Not checked yetcites [67] Rey, 1979, Pharmacokinetics of the placental transfer and distribution of clorazepate and its metabolite nordiazepam in the feto-placental unit and in the neonate, Eur J Clin Pharmacol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Additionally, many elderly individuals take multiple medications, which increase their risk of drug-drug interactions.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Increased sensitivity of older patients to BZDs is partly due to reduced drug metabolism (when compared with younger adults), which can result in drug accumulation (62).”
What the sources say
- Not checked yetcites [62] Demaagd, 1995, High-risk drugs in the elderly population, Geriatr Nurs source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonazepam and lorazepam undergo extensive metabolism, but no active metabolites are formed (18,24).”
What the sources say
- Not checked yetcites [18] Nelson, 1999, Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal, Can J Clin Pharmacol
- Not checked yetcites [24] Anderson, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“By contrast, clorazepate undergoes rapid and complete chemical conversion to DMD in the gastrointestinal tract; its pharmacologic effects are largely due to DMD (24,56).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [56] Breimer, 1980, Pharmacokinetics of benzodiazepines. Short-acting versus long-acting, Arzneimittelforschung
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, BZD pharmacologic effects appear to be greater in elderly patients than in younger patients even at similar plasma BZD concentrations (63,64), possibly because of age-related changes in drug-receptor interactions, post-receptor mechanisms and organ function.”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As discussed earlier, BZD metabolism is complex and largely catalyzed by CYP isoenzymes.Consequently, there is potential for interactions between BZDs and drugs that induce or inhibit CYP isoenzymes.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Oral contraceptive steroids may inhibit the metabolism of some BZDs that undergo oxidative metabolism or nitroreduction and accelerate the metabolism of some BZDs that are conjugated.”
What the sources say
- Not checked yetcites [60] Back, 1990, Pharmacokinetic drug interactions with oral contraceptives, Clin Pharmacokinet source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Some BZDs are also available as oral liquids [diazepam (Diazepam Intensol; 5 mg ⁄ ml), lorazepam (Lorazepam Intensol; 2 mg ⁄ ml) and midazolam (generic only; 2 mg ⁄ ml)], disintegrating tablets [clonazepam (Klonopin Ò Wafer; Roche Pharmaceuticals, Nutley, NJ, USA; 0.125-, 0.25-, 0.5-, 1-and 2-mg tablets)] or a rectal gel [diazepam (Diastat Ò AcuDial; Valeant Pharmaceuticals International, Costa M”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“For example, inhibition of a minor pathway may have little impact on drug concentration, whereas inhibition of a major pathway may result in enhanced clinical effect or toxicity.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cytochrome P-450-catalyzed metabolism tends to be low at birth, but exceeds adult values by age 2-3 years; thereafter, CYP-catalyzed metabolism decreases, reaching adult levels around puberty (66).”
What the sources say
- Not checked yetcites [66] Anderson, 2002, Children versus adults: pharmacokinetic and adverse-effect differences, Epilepsia source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Midazolam is rapidly converted by CYP 3A4 and CYP 3A5 to 1-hydroxymidazolam, which contributes approximately 10% to the biologic activity of its parent drug (24,41).”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [41] Gorski, 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily, Biochem Pharmacol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Elderly individuals often have variable drug absorption, decreased plasma protein-drug binding due to lower albumin concentrations, and reduced hepatic and renal clearance (61).”
What the sources say
- Not checked yetcites [61] Patsalos, 2002, The importance of drug interactions in epilepsy therapy, Epilepsia source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Extended-release drug formulations can help patients with epilepsy achieve their primary treatment goals of controlling seizures while reducing side effects by minimizing fluctuations in drug concentration and by improving compliance.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the Veterans Affairs cooperative study of status epilepticus, lorazepam terminated seizures in 64.9% of patients and was significantly more effective than phenytoin (P = 0.002) (79).”
What the sources say
- Not checked yetcites [79] Treiman, 1998, A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Fewer studies have evaluated the clinical efficacy of BZDs in chronic epilepsy.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Results from four comparative studies (three of blinded design) have suggested that lorazepam is superior to phenytoin and as effective as clonazepam, diazepam or the combination of diazepam and phenytoin in the initial treatment of status epilepticus (77,79,80,96).”
What the sources say
- Not checked yetcites [77] Alldredge, 2001, A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus, N Engl J Med source
- Not checked yetcites [79] Treiman, 1998, A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group, N Engl J Med source
- Not checked yetcites [80] Leppik, 1983, Double-blind study of lorazepam and diazepam in status epilepticus, JAMA source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines were used in epilepsy management as early as 1965, when Gastaut et al. (73,74) administered i.v.diazepam to treat status epilepticus.”
What the sources say
- Not checked yetcites [73] Gastaut, 1965, Treatment of status epilepticus with diazepam (Valium), Epilepsia source
- Not checked yetcites [74] Gastaut, 1965, Laction du diazepam (Valium) dans le traitement des formes non-convulsive de lepilepsie generalisee [in French], Rev Neurol (Paris)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Benzodiazepines are among the most useful AEDs available for treating status epilepticus and acute repetitive seizures and for febrile seizure prophylaxis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, when a missed daily dose was replaced, the sustainedrelease formulation resulted in a smaller change in peak concentrations, which may reduce the risk of drug toxicity.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Changes in simulated plasma DMD peak-to-trough concentrations correspond to clinical risks of breakthrough seizures and drug toxicity.
In the paper
“Therefore, multiple injections or continuous infusion may be required, which can lead to drug accumulation and possibly to acute respiratory depression, sedation and hypotension (76).”
What the sources say
- Not checked yetcites [76] Schmidt, 2002
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Diazepam is a drug of first choice for treatment of early status epilepticus and acute repetitive seizures and for febrile seizure prophylaxis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In one study, 70% of children with absence seizures treated with clonazepam (seven of 10) had a ‡ 75% reduction in seizure frequency after 8 weeks of treatment, and an additional 10% of children (one of 10) had a 30% reduction in seizure frequency (105).”
What the sources say
- Not checked yetcites [105] Dreifuss, 1975, Serum clonazepam concentrations in children with absence seizures, Neurology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In a randomized trial comparing buccal midazolam with rectal diazepam in children, the drugs showed similar efficacy and onset of action (125).”
What the sources say
- Not checked yetcites [125] Scott, 1999, Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although it is used for many seizure types, midazolam does not have an FDA-approved indication for seizures.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Therapeutic success (defined as cessation of visible signs of seizure activity within 10 min of drug administration, lack of respiratory depression and no further seizures within 1 h) was noted in 56% of midazolam-treated patients (61 of 109) and 27% of diazepam-treated patients (30 of 110), a 29% difference between groups; (95% confidence interval, 16-41%).”
What the sources say
- Not checked yetcites [134] McIntyre, 2005, Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In that study, seizure cessation was achieved in 75% of cases ( 30 of 40)with midazolam and in 59% of cases (23 of 39) with diazepam treatment (P = 0.16).”
What the sources say
- Not checked yetcites [125] Scott, 1999, Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Although not currently approved in the USA, clobazam is commonly used elsewhere as adjunctive therapy for patients with refractory epilepsy (103).”
What the sources say
- Not checked yetcites [103] Trimble, 2002, On the use of tranquillisers in epilepsy, Epilepsia source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Midazolam is the only available water-soluble BZD; solubility is achieved when the injectable solution is buffered to a pH of 2.9-3.7 (123).”
What the sources say
- Not checked yetcites [123] 123.Midazolam HCl injection [package insert]. Weston, FL: Apotex Corp, 2000.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clobazam was studied in a large double-blind trial as first-line monotherapy in children with partial, partial with secondary generalization or primary generalized tonic-clonic seizures and was reported to have efficacy and tolerability similar to that of monotherapy with phenytoin or carbamazepine (153, 154).”
What the sources say
- Not checked yetcites [153] Canadian Study Group for Childhood Epilepsy, 1998, Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy, Epilepsia source
- Not checked yetcites [154] Bawden, 1999, The cognitive and behavioural effects of clobazam and standard monotherapy are comparable, Epilepsy Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Open-label studies have suggested that intranasal midazolam is safe and effective for acute seizure management in children (124, 127, 128, 135, 136).”
What the sources say
- Not checked yetcites [124] Lahat, 2000, Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study, BMJ source
- Not checked yetcites [127] Fisgin, 2002, Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study, J Child Neurol source
- Not checked yetcites [128] Mahmoudian, 2004, Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children, Epilepsy Behav source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“with 88% of seizures (23 of 26) responding to initial treatment with midazolam and 92% (24 of 26) responding to diazepam (124).”
What the sources say
- Not checked yetcites [124] Lahat, 2000, Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study, BMJ source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It is highly effective as adjunctive therapy for partial and generalized seizures, for intermittent therapy and for controlling nonconvulsive status epilepticus”
What the sources say
- Not checked yetcites [140] Shorvon, 1998, The use of clobazam, midazolam, and nitrazepam in epilepsy, Epilepsia source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“studies have suggested that intranasal midazolam is safe and effective for acute seizure management in children (124, 127, 128, 135, 136).”
What the sources say
- Not checked yetcites [124] Lahat, 2000, Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study, BMJ source
- Not checked yetcites [127] Fisgin, 2002, Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study, J Child Neurol source
- Not checked yetcites [128] Mahmoudian, 2004, Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children, Epilepsy Behav source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, pain is common with intranasal midazolam administration, which may indicate irritation of the nasal mucosa due to the low pH (3-4.3) of the formulation (137-139).”
What the sources say
- Not checked yetcites [137] Scott, 2001, Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam [letter], BMJ source
- Not checked yetcites [138] Loftsson, 2001, Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray, Int J Pharm source
- Not checked yetcites [139] Gudmundsdttir, 2001, Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans, Pharmazie
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A large volume is required to deliver a therapeutic dose, making administration difficult because much of the solution may leak out of the nose or be swallowed (137).”
What the sources say
- Not checked yetcites [137] Scott, 2001, Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam [letter], BMJ source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Paradoxical excitement is sometimes associated with BZD use and may include exacerbation of seizures in patients with epilepsy (171).”
What the sources say
- Not checked yetcites [171] Gayatri, 2006, Aggravation of epilepsy by anti-epileptic drugs, Dev Med Child Neurol source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“and although diazepam impairs explicit memory, results regarding impairment of implicit memory by diazepam are mixed (176-179).”
What the sources say
- Not checked yetcites [176] Legrand, 1995, Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory, Psychopharmacology source
- Not checked yetcites [177] Wagemans, 1998, Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments, Psychopharmacology source
- Not checked yetcites [178] Vidailhet, 1994, Lorazepam and diazepam effects on memory acquisition in priming tasks, Psychopharmacology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Benzodiazepine use is also associated with falls, a possible result of over-sedation in elderly patients (167).”
What the sources say
- Not checked yetcites [167] Souchet, 2005, Drug related falls: a study in the French pharmacovigilance database, Pharmacoepidemiol Drug Saf source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Over-sedation is more problematic in the elderly than in younger patients, and it may occur at lower doses in the elderly (165, 166).”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“High BZD dosage and potency, short duration of BZD action, long duration of therapy and premorbid dependent personality traits are risk factors for the development of BZD dependence (173).”
What the sources say
- Not checked yetcites [173] Marriott, 1993, Benzodiazepine dependence. Avoidance and withdrawal, Drug Saf source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lorazepam appears to impair both explicit memory and implicit memory”
What the sources say
- Not checked yetcites [176] Legrand, 1995, Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory, Psychopharmacology source
- Not checked yetcites [177] Wagemans, 1998, Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments, Psychopharmacology source
- Not checked yetcites [178] Vidailhet, 1994, Lorazepam and diazepam effects on memory acquisition in priming tasks, Psychopharmacology source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This effect is sometimes deliberately utilized in presurgical medication (169).”
What the sources say
- Not checked yetcites [169] Ranta, 2002, Patients conscious recollections from cardiac anesthesia, J Cardiothorac Vasc Anesth source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, although BZDs are generally known to affect memory, some studies have shown that effects differ depending on the BZD used.”
What the sources say
- Not checked yetcites [176] Legrand, 1995, Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory, Psychopharmacology source
- Not checked yetcites [177] Wagemans, 1998, Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments, Psychopharmacology source
- Not checked yetcites [178] Vidailhet, 1994, Lorazepam and diazepam effects on memory acquisition in priming tasks, Psychopharmacology source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In that study, an excellent response (defined as complete seizure control or seizure control that produced a notable improvement in social, educational or vocational assessment) was observed for 19% of patients with major generalized seizures (three of 16), 39% of patients with absence seizures (seven of 18), 33% of patients with akinetic seizures (three of nine) and 57% of patients with myoclonic”
What the sources say
- Not checked yetcites [155] Booker, 1974, Clorazepate dipotassium in the treatment of intractable epilepsy, JAMA source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Elderly patients treated with BZDs can experience confusion, amnesia, ataxia and hangover effects (62).”
What the sources say
- Not checked yetcites [62] Demaagd, 1995, High-risk drugs in the elderly population, Geriatr Nurs source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Young et al. (185) found that tolerance to clobazam developed within 3 days of initial drug exposure, whereas tolerance to clonazepam developed gradually over the course of a 19-day study.”
What the sources say
- Not checked yetcites [185] Young, 1988, Differences in the development of tolerance to two anticonvulsant benzodiazepines in the amygdaloid kindled rat, J Pharm Pharmacol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Other shortcomings include adverse events, such as cognitive impairment and sedation, and drug interactions.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“The authors suggested that differences in tolerance and crosstolerance could result from differential regulation of receptor subunit expression by each drug and from differences between the drugs in their interactions with receptors at the time of testing.”
What the sources say
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“They have the clinical advantages of being highly effective, with a rapid onset of action and relatively low toxicity.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Rats treated with midazolam for 3 weeks developed cross-tolerance to diazepam but not to clobazam or clonazepam.”
What the sources say
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines can be used in a variety of clinical situations because they can be administered by several routes and in different formulations.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“When BZDs are used as anticonvulsants, the time to onset of tolerance varies, and the potential of a BZD to induce anticonvulsant tolerance does not appear to have any relationship with its chemical or pharmacokinetic properties (188).”
What the sources say
- Not checked yetcites [188] Garratt, 1988, Can benzodiazepines be classified by characterising their anticonvulsant tolerance-inducing potential?, Eur J Pharmacol source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cross-tolerance between BZDs occurs and appears to be drug specific.”
What the sources say
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Clobazam | Demethylation (26) | N-desmethylclobazam (27) | 10-30 (28) | 36-46 (28)”
What the sources say
- Not checked yetcites [28] Rupp, 1979, Pharmacokinetics of single and multiple doses of clobazam in humans, Br J Clin Pharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonazepam | Nitroreduction (CYP 3A4), | NA | 19-60 (32) | NA”
What the sources say
- Not checked yetcites [29] Seree, 1993, Fundam Clin Pharmacol source
- Not checked yetcites [30] Miller, 1981, Clonazepam acetylation in fast and slow acetylators, Clin Pharmacol Ther source
- Not checked yetcites [31] Peng, 1984, Polymorphic acetylation of 7-amino-clonazepam in human liver cytosol, Pediatr Pharmacol (New York)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Clorazepate is unique among BZDs in that it is associated with slow onset of tolerance, its active metabolite has a long t 1 ⁄ 2 , and it is available as a sustained-release formulation”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Benzodiazepines are indicated for the treatment of seizure emergencies and epilepsy.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Studies of clorazepate in patients with epilepsy have mainly been small, open-label investigations.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“Gobbi et al. (199) demonstrated that diazepam and DMD have the same affinity for the central type of BZD receptors, but when the intrinsic activity of DMD was calculated, it proved to be a partial agonist, with intrinsic activity approximately 43% that of diazepam.”
What the sources say
- Not checked yetcites [199] Gobbi, 1987, Diazepam and desmethyldiazepam differ in their affinities and efficacies at central and peripheral benzodiazepine receptors, J Pharm Pharmacol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“One putative mechanism for the development of tolerance is simple down-regulation of GABA receptors in response to prolonged BZD exposure; however, studies testing this hypothesis have reported mixed results (197).”
What the sources say
- Not checked yetcites [197] Bateson, 2002, Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal, Curr Pharm Des source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Several other mechanisms for BZD tolerance have been proposed on the basis of animal and cell culture models.These processes include uncoupling of allosteric linkage between GABA and BZD sites, changes in the turnover of receptor subunits and changes in receptor gene expression (197).”
What the sources say
- Not checked yetcites [197] Bateson, 2002, Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal, Curr Pharm Des source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“all of which may, theoretically, help minimize adverse effects and withdrawal symptoms.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Li et al. (198) suggested that down-regulation of BZD receptor binding sites could not fully explain the development of tolerance because tolerance to some BZDs has been observed even when no changes in BZDreceptor binding were noted (187).”
What the sources say
- Not checked yetcites [198] Li, 2000, Down-regulation of benzodiazepine binding to alpha-5 subunit-containing gamma-aminobutyric acidA receptors in tolerant rat brain indicates particular involvement of the hippocampal CA1 region, J Pharmacol Exp Ther
- Not checked yetcites [187] Ramsey-Williams, 1994, Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam, Pharmacol Biochem Behav source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“However, results from other studies have suggested that, compared with long-t 1 ⁄ 2 BZDs, BZDs with short t 1 ⁄ 2 are associated with faster onset of withdrawal symptoms or more severe withdrawal symptoms when BZD therapy is stopped abruptly (211, 212).”
What the sources say
- Not checked yetcites [211] Rickels, 1990, Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation [erratum in Arch Gen Psychiatry 1991;48:51], Arch Gen Psychiatry source
- Not checked yetcites [212] Busto, 1986, Withdrawal reaction after long-term therapeutic use of benzodiazepines, N Engl J Med source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clobazam | Demethylation (26) | N-desmethylclobazam (27) | 10-30 (28) | 36-46 (28)”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clorazepate | Decarboxylation, glucuronidation, | DMD (major), oxazepam (minor) (24) | NA | 20-160 (24, 33, 34)”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [33] Greenblatt, 1988, Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam, J Clin Pharmacol source
- Not checked yetcites [34] Bertler, 1980, Pharmacokinetics of dipotassium chlorazepate in patients after repeated 50mg oral doses, Psychopharmacology (Berl) source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, tolerance may recur at the higher dose, and adverse effects may persist or worsen.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Tolerance may develop over time, making BZDs unsuitable for use in long-term epilepsy management.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Rosenberg et al. (189) compared the anticonvulsant activity of clonazepam, clobazam and diazepam in rats and found that tolerance developed most rapidly to clobazam and most slowly to clonazepam.”
What the sources say
- Not checked yetcites [189] Rosenberg, 1989, Tolerance to anticonvulsant effects of diazepam, clonazepam, and clobazam in amygdala-kindled rats, Epilepsia source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Additionally, withdrawal symptoms, some severe, may develop after cessation of BZD therapy.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“Considering the evidence that tolerance to the various behavioral effects of BZDs develops at different rates and that behavioral effects of BZDs are mediated by different GABA A receptor subtypes, Bateson (197) proposed that multiple mechanisms mediate tolerance and dependence.He described a unified model of molecular mechanisms underlying tolerance that incorporates the molecular processes”
What the sources say
- Not checked yetcites [197] Bateson, 2002, Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal, Curr Pharm Des source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- The authors state this as an assumption: In Bateson's unified model, initial potentiation of the GABA response leads to desensitization, and prolonged desensitization could result in uncoupling as either a signal for or a consequence of receptor internalization.
- The authors state this as an assumption: After receptor internalization, degradation of certain receptor subunits could provide a signal for changes in GABA A receptor gene transcription.
In the paper
“Tolerance occurred in 48% of patients treated with clorazepate for ‡4 weeks, but in only 24% of patients treated with clobazam for ‡3 months (193).”
What the sources say
- Not checked yetcites [193] Sugai, 2004, Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan, Epilepsia source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Some reports have suggested that BZD t 1 ⁄ 2 does not influence withdrawal symptoms (208, 210).”
What the sources say
- Not checked yetcites [208] Schweizer, 1990, Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper, Arch Gen Psychiatry source
- Not checked yetcites [210] Murphy, 1991, A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence, Br J Psychiatry source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Numerous reports have identified certain predictors of the occurrence or increased severity of withdrawal symptoms: higher BZD dose (200-204), longer duration of BZD use (202, 203, 205, 206), immediate cessation or rapid tapering of the BZD dose (200, 203, 204, 207-209), history of drug abuse (202, 203), dependence on other drugs (209), personality pathology (e.g.neuroticism and dependency) (203)”
What the sources say
- Not checked yetcites [200] Martnez-Cano, 1995, Benzodiazepine withdrawal syndrome seizures, Pharmacopsychiatry source
- Not checked yetcites [202] Uhlenhuth, 1999, International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders, J Clin Psychopharmacol source
- Not checked yetcites [203] Schweizer, 1998, Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management, Acta Psychiatr Scand Suppl source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clorazepate | Tranxene T-Tab | Yes | Anxiety, alcohol withdrawal, | Adjunctive treatment of partial seizures (75)”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clobazam | Frisium | NA | Not FDA approved | First-line adjunctive treatment for treatment-resistant”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lorazepam | Glucuronidation (24) | NA | 7-26 (39, 40) | NA”
What the sources say
- Not checked yetcites [24] Anderson, 2002
- Not checked yetcites [39] Greenblatt, 1979, Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans, J Pharm Sci source
- Not checked yetcites [40] Greenblatt, 1982, Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam, J Pharm Sci source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Diazepam | Demethylation (CYP 2C9, 2C19, 2B6, 3A4, | DMD (major), oxazepam (minor), | 21-70 (23, 38) | DMD: 49-179 (33, 38)”
What the sources say
- Not checked yetcites [23] Cloyd, 1998, A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam, Epilepsia source
- Not checked yetcites [38] Kaplan, 1973, Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations, J Pharm Sci source
- Not checked yetcites [24] Anderson, 2002
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Midazolam | Versed | Yes | Anesthesia, preoperative and procedural | Second-line therapy for early status epilepticus”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonazepam | Klonopin | Yes | Panic disorder, epileptic | Second-line adjunctive treatment for partial and”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Midazolam | Hydroxylation (CYP 3A4 and 3A5) (25, 41, 42) | 1-hydroxymidazolam (minor) (24) | 1-4 (24) | 1 (24)”
What the sources say
- Not checked yetcites [25] Hobbs, 1996
- Not checked yetcites [41] Gorski, 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily, Biochem Pharmacol source
- Not checked yetcites [42] Kronbach, 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4, Mol Pharmacol
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Diazepam | Valium | Yes | Anxiety, alcohol withdrawal, | First-line treatment for early status epilepticus;”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Lorazepam | Ativan | Yes | Anxiety, pre-anesthetic to induce amnesia, | First-line treatment for early status epilepticus”
What the sources say
- Not checked yetcites [75] Lacy, 2004
- Not checked yetcites [76] Schmidt, 2002
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
The paper relies on this without support.
Changes in simulated plasma DMD peak-to-trough concentrations correspond to clinical risks of breakthrough seizures and drug toxicity.
“This effect may prevent breakthrough seizures in some patients.”
“which may reduce the risk of drug toxicity.”
The paper relies on this without support.
Tolerance to antiepileptic drugs is associated with a progressive increase in the number and severity of seizures and an increased risk of withdrawal seizures when the maintenance dose is constant.
“Tolerance to AEDs is associated with a progressive increase in the number and severity of seizures and an increased risk of withdrawal seizures in the presence of a constant maintenance dose.”
The authors state this as an assumption.
In Bateson's unified model, initial potentiation of the GABA response leads to desensitization, and prolonged desensitization could result in uncoupling as either a signal for or a consequence of receptor internalization.
“This model assumes that initial potentiation of the GABA response leads to desensitization and that prolonged desensitization could result in uncoupling (as either a signal for or a consequence of receptor internalization, i.e. endocytosis).”
The authors state this as an assumption.
After receptor internalization, degradation of certain receptor subunits could provide a signal for changes in GABA A receptor gene transcription.
“Subsequent to receptor internalization, degradation of certain receptor subunits could provide a signal for changes in GABA A receptor gene transcription.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, the concomitant use of B. monnieri with clinically prescribed drugs that are substrates of CYP3A4, CYP2C9, and CYP2C19 isoforms, particularly those exhibiting poor bioavailability due to extensive metabolism such as clozapine [31] and midazolam [32] could cause potential herb-drug interactions.”
From Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Special formulations of BZDs
“These simulations were briefly described by Kaplan and DuPont (72), but detailed results are reported herein.”
§ References
“71. Kaplan EM, Dupont RL. Benzodiazepines and anxiety disorders: a review for the practicing physician. Curr Med Res Opin 2005;21:941-50.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metabolism and elimination
“short acting (<10 h; lorazepam, midazolam)”
§ Conclusions
“| Lorazepam | Glucuronidation (24) | NA | 7-26 (39, 40) | NA |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metabolism and elimination
“intermediate acting (10-24 h; clonazepam)”
§ Conclusions
“| Clonazepam | Nitroreduction (CYP 3A4), | NA | 19-60 (32) | NA |”
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Epilepsy: A Comprehensive Textbook
(2008) · JAMA · doi:10.1001/jama.300.4.443-a · Cited by 2,357
Macdonald, R. L., & Olsen, R. W. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.003033 · Cited by 1,975
A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus
Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391202 · Cited by 1,325
Which GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
Alldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002141 · Cited by 888
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716
Jerram, T. C. (1981) · Side effects of drugs annual · doi:10.1016/s0378-6080(81)80009-8 · Cited by 695
Research works printed but not linked: 26
- International Narcotics Control Board, Psychotropic Substances 2006
- Shorvon, 1995, Antiepileptic drugs, 763
- Anderson, 2002, Antiepileptic drugs, 187
- Hobbs, 1996, Goodman & Gilmans. The pharmacological basis of therapeutics, 361
- United Nations, 1997, Recommended methods for the detection and assay of barbiturates and benzodiazepines in biological specimens. Manual for use by national laboratories
- Flockhart, Drug interaction table (cytochrome P450 system)
- 47.Trileptal [package insert]. East Hanover, NJ: Novartis, 2007.
- Lacy, Anticonvulsants and antimicrobial cytochrome P-450 effects
- Goshman, 1999, Clinically significant P450 drug interactions, J Pharm Soc Wisconsin, 23
- Riss, The simulation of desmethyldiazepam (DMD) concentrations following missed daily doses of Tranxene-SD and Tranxene T-Tab
- Gastaut, 1965, Laction du diazepam (Valium) dans le traitement des formes non-convulsive de lepilepsie generalisee [in French], Rev Neurol (Paris), 112, 99
- Schmidt, 2002, Antiepileptic drugs, 206
- Schmidt, 1995, Antiepileptic drugs, 705
- Sato, 1995, Antiepileptic drugs, 725
- Sato, 1977, Clonazepam in the treatment of absence seizures: a double-blind clinical trial [abstract], Neurology, 27, 371
- Beck, 1973, Traitement des etats de mal epileptiques par le clonazepam [in French], Sem Hop Paris, 49, 21
- Bergamini, 1970, Elektroenzephalographische und klinische Bewertung des neuen Benzodiazepin Ro 54023 [in German], EEG EMG, 1, 182
- Bergamini, 1972, LAction du Ro 54023 dans le traitement des differentes formes depilepsie [in French]
- Gastaut, 1970, Properties anti-epileptiques exceptionneles dune benzodiazepine nouvelle le Ro 05-4023 [in French], La Vie Medicale, 51, 5175
- Gimenez-Roldan, 1972, Un nuevo medicamento eficaz en el trataimento del status epilepticus - Ro 5-4023 [in Spanish], Med Clin (Barc), 58, 133
- Tridon, 1973, Conduite du traitement des etats de mal epileptiques par le Ro 05-4023 (clonazepam) [in French], Sem Hop Paris, 49, 29
- 123.Midazolam HCl injection [package insert]. Weston, FL: Apotex Corp, 2000.
- Wolf, 1985, Clobazam. Human psychopharmacology and clinical application, 167
- Critchley, 1981, Clobazam, 159
- Wilson, 1985, Clobazam. Human psychopharmacology and clinical application, 172
- Graf, 1987, Clorazepate therapy in children with refractory seizures [abstract], Epilepsia, 28, 606
Cited by
Sorted by citations
Items 101–200 of 508
Halogenated Heterocycles as Pharmaceuticals
Kosjek, T., & Heath, E. (2011) · Topics in heterocyclic chemistry · doi:10.1007/7081_2011_61 · Cited by 32
Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome
Fridley, B. L., Armasu, S. M., Cicek, M. S., Larson, M. C., Wang, C., Winham, S. J., Kalli, K. R., Koestler, D. C., Rider, D. N., Shridhar, V., et al. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-21 · Cited by 31
Premedication With Midazolam Nasal Spray: An Alternative to Oral Midazolam in Children
Verma, R., Paswan, A. K., De, A., & Gupta, S. K. (2011) · Anesthesiology and Pain Medicine · doi:10.5812/aapm.4567 · Cited by 31
How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective
Gu, J.-N., Guo, Y., Jiao, Z., Ding, J., & Li, G. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00598-0 · Cited by 31
Chan, T., Leung, W. C. Y., Li, V., Wong, K. W., Chu, W.-M., Leung, K. C., Ng, Y.-Z., Kai, Y. G., Shea, Y. F., Chang, S. R., et al. (2017) · Psychogeriatrics · doi:10.1111/psyg.12239 · Cited by 31
A Mesiotemporal Lobe Epilepsy Mouse Model
Duveau, V., & Roucard, C. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2239-3 · Cited by 31
Cognitive behavioral therapy-related increases in cortical inhibition in problematic perfectionists
Radhu, N., Daskalakis, Z. J., Guglietti, C. L., Farzan, F., Barr, M. S., Arpin-Cribbie, C. A., Fitzgerald, P. B., & Ritvo, P. (2012) · Brain Stimulation · doi:10.1016/j.brs.2011.01.006 · Cited by 30
Combined occlusal and pharmacological therapy in the treatment of temporo-mandibular disorders.
Inchingolo, F., Tatullo, M., Marrelli, M., Am, I., Tarullo, A., Ad, I., Dipalma, G., Podo Brunetti, S., Tarullo, A., & Cagiano, R. (2011) · PubMed · Cited by 30
Chen, M., Hill, G. M., Patrianakos, T. D., Ku, E. S., & Chen, M. L. (2015) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2014.06.027 · Cited by 30
Leufkens, T., Ramaekers, J. G., de Weerd, A. W., Riedel, W. J., & Vermeeren, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3455-z · Cited by 31
Benzodiazepines for prolonged seizures
Anderson, M. (2010) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2009.176321 · Cited by 29
Duveau, V., Buhl, D. L., Evrard, A., Ruggiero, C., Mandé‐Niedergang, B., Roucard, C., & Gurrell, R. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13046 · Cited by 29
Thalamic and cortical hyperexcitability in juvenile myoclonic epilepsy
Assenza, G., Lanzone, J., Dubbioso, R., Coppola, A., Boscarino, M., Ricci, L., Insola, A., Bilo, L., Tombini, M., & Lazzaro, V. D. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.04.164 · Cited by 28
Semicarbazone – a versatile therapeutic pharmacophore for fragment based anticonvulsant drug design
Pandeya, S. N. (2012) · Acta Pharmaceutica · doi:10.2478/v10007-012-0030-1 · Cited by 28
Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy
Sperling, M. R., Haas, K. F., Krauss, G. L., Eddeine, H. S., Henney, H. R., Rabinowicz, A. L., Bream, G., Squillacote, D., & Carrazana, E. J. (2014) · Epilepsia · doi:10.1111/epi.12755 · Cited by 28
Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy
Patel, S., Birnbaum, A. K., Cloyd, J. C., & Leppik, I. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0289-0 · Cited by 28
Self-citationSivakumar, S. S., Namath, A. G., Tuxhorn, I., Lewis, S. J., & Galán, R. F. (2016) · Journal of Neurophysiology · doi:10.1152/jn.01120.2015 · Cited by 28
Muglia, P., Hannestad, J. O., Brandt, C., DeBruyn, S., Germani, M., Lacroix, B. D., Majoie, M., Otoul, C., Sciberras, D. G., Steinhoff, B. J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa183 · Cited by 27
Trenité, D. G. A. K.-N., Groenwold, R. H. H., Schmidt, B., & Löscher, W. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.02.003 · Cited by 27
Cao, Y., Yan, H. F., Yu, G., & Su, R. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117033 · Cited by 26
Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy
Sheibani, M., Shayan, M., Khalilzadeh, M., Ghasemi, M., & Dehpour, A. R. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102335 · Cited by 28
Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters
Gidal, B. E., Maganti, R. K., Laurenza, A., Yang, H., Verbel, D., Schuck, E. L., & Ferry, J. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.04.018 · Cited by 26
Lagae, L. G. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1403-z · Cited by 25
Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome
Cramer, J. A., Sapin, C., & François, C. (2013) · Acta Neurologica Scandinavica · doi:10.1111/ane.12086 · Cited by 25
Kim, H. J., Park, B. K., & Chung, I. S. (2017) · Canadian Association of Radiologists Journal · doi:10.1016/j.carj.2017.07.003 · Cited by 25
Beyzaei, H., Khosravi, Z., Aryan, R., & Ghasemi, B. (2019) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-019-01714-2 · Cited by 25
Dantas, L. M. S., & Ogata, N. (2023) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.07.003 · Cited by 25
Hamburger, M. O. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1606261 · Cited by 24
Qiu, Z.-K., Liu, Z., Pang, J., Wu, H.-B., Liu, X., Yang, Z.-M., Li, X., & Chen, J. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00816-2 · Cited by 24
Successful treatment of hepatic failure secondary to diazepam administration in a cat
Park, F. M. (2012) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x11432238 · Cited by 24
Erfanparast, A., & Tamaddonfard, E. (2015) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2015-2028 · Cited by 24
Clobazam therapy of refractory epilepsy in tuberous sclerosis complex
Jennesson, M. M., van Eeghen, A. M., Caruso, P. A., Paolini, J. L., & Thiele, E. A. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.10.010 · Cited by 24
Gangurde, P. K., Bhaskaran, N. A., & Kumar, L. (2018) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-018-9343-z · Cited by 25
Review and Updates on the Treatment of Refractory and Super Refractory Status Epilepticus
Alolayan, Y. S., McKinley, K., Bhatia, R., & Alkhachroum, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143028 · Cited by 23
Honeychurch, K. C., & Hart, J. P. (2014) · Insciences Journal · doi:10.5640/insc.040101 · Cited by 23
Fu, K., Miyamoto, Y., Sumi, K., Saika, E., Muramatsu, S., Uno, K., & Nitta, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189006 · Cited by 23
Drug Interactions of Psychiatric and COVID-19 Medications
Mohebbi, N., Talebi, A., Moghadamnia, M., Nazari, Z., & Shakiba, A. (2020) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.11.covid19.2500.1 · Cited by 23
Thomaidou, M. A., Peerdeman, K. J., Koppeschaar, M. I., Evers, A. W. M., & Veldhuijzen, D. S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.652552 · Cited by 22
Li, X., Mei, X., Xu, L., Shen, X., Zhu, W., Hong, J., & Zhou, X. (2016) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2016.01.072 · Cited by 22
Update on Antiseizure Medications 2025
Abou-Khalil, B. W. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001521 · Cited by 20
Sefidan, A. M., & Rezaie, A. R. (2013) · Cited by 21
Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study
Brodie, M. J., Chung, S. S., Wade, A. G., Quelen, C., Guiraud-Diawara, A., François, C., Verpillat, P., Shen, V., & Isojärvi, J. I. T. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.04.003 · Cited by 21
Manthey, L., Giltay, E. J., van Veen, T., Neven, A. K., Zitman, F. G., & Penninx, B. W. J. H. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182362484 · Cited by 21
Chen, G., Nomikos, G. G., Affinito, J., & Zhao, Z. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0389-0 · Cited by 22
Ashrafi, H., Mobed, A., Hasanzadeh, M., Babaie, P., Ansarin, K., & Jouyban, A. (2018) · Microchemical Journal · doi:10.1016/j.microc.2018.12.064 · Cited by 21
Mouro, F. M., Miranda‐Lourenço, C., Sebastião, A. M., & Diógenes, M. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00680 · Cited by 22
Application of aromatic plants and their extracts in the diets of laying hens
Harrington, D., Hall, H., Wilde, D., & Wakeman, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814700-9.00011-x · Cited by 21
Monoterpenes as a perspective for the treatment of seizures: A Systematic Review
Pina, L. T. S., Guimarães, A. G., Santos, W. B. D. R., Oliveira, M. A., Rabelo, T. K., & Serafini, M. R. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153422 · Cited by 21
Clonazepam in the treatment of status epilepticus
Shangguan, Y., Liao, H., & Wang, X. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1056781 · Cited by 20
Pflanz, C. P., Pringle, A., Filippini, N., Warren, M., Gottwald, J., Cowen, P. J., & Harmer, C. J. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3844-3 · Cited by 21
New Antiepileptic Drugs: Focus on Ezogabine, Clobazam, and Perampanel
Rudzinski, L. A., Velez-Ruiz, N. J., Gedzelman, E. R., Mauricio, E. A., Shih, J. J., & Karakis, I. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000151 · Cited by 20
Dhir, A., & Rogawski, M. A. (2018) · Epilepsia · doi:10.1111/epi.14069 · Cited by 20
Effect of psychiatric drugs on Daphnia magna oxylipin profiles
Garreta‐Lara, E., Checa, A., Fuchs, D., Tauler, R., Lacorte, S., Wheelock, C. E., & Barata, C. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.06.333 · Cited by 20
dos Santos, F. M., Gonçalves, J. C. S., Caminha, R. C., da Silveira, G. E., Neves, C. S. D. M., Gram, K. R. D. S., Ferreira, C. T., Jacqmin, P., & Noël, F. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181b1dd76 · Cited by 20
Pretreatment-free detection of diazepam in beverages based on a thermometric biosensor
Xu, N., Bai, J., Peng, Y. Y., Qie, Z., Liu, Z., Tang, H., Liu, C., Gao, Z., & Ning, B. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.10.081 · Cited by 19
Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome
Fisher, J. L., Chu-Shore, & Leahy, J. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s20173 · Cited by 18
One-Pot Synthesis of 4-Substituted-1,5-Benzodiazepines Promoted by Tris(Hydrogensulfato) Boron
Karimi‐Jaberi, Z., & Hooshmandpour, A. (2018) · Polycyclic aromatic compounds · doi:10.1080/10406638.2018.1441876 · Cited by 18
Carbonic anhydrase inhibitors suppress seizures in a rat model of birth asphyxia
Pospelov, A. S., Ala‐Kurikka, T., Kurki, S., Voipio, J., & Kaila, K. (2021) · Epilepsia · doi:10.1111/epi.16963 · Cited by 18
Reddy, D. S., Mbilinyi, R. H., & Ramakrishnan, S. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114240 · Cited by 19
Desensitization of GABAergic receptors as a mechanism of zolpidem-induced somnambulism
Juszczak, G. R. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.04.019 · Cited by 18
Withdrawal-related adverse events from clinical trials of clobazam in Lennox–Gastaut syndrome
Tolbert, D. S., Harris, S. I., Bekersky, I., Lee, D., & Isojärvi, J. I. T. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.05.016 · Cited by 18
Atack, J. R. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_2 · Cited by 18
[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics].
Vinkers, C. H., Tijdink, J. K., Luykx, J. J., & Vis, R. (2012) · PubMed · Cited by 18
Design, Synthesis, and Evaluation of Anticonvulsant Activities of New Triazolopyrimidine Derivatives
Song, M., Zhao, W., Zhu, Y., Liu, W., Deng, X., & Huang, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.925281 · Cited by 17
Racamonde, I., Quintana, J. B., Rodil, R., & Cela, R. (2014) · Microchemical Journal · doi:10.1016/j.microc.2014.10.011 · Cited by 17
Prenatal exposure to benzodiazepines and the development of the offspring – a systematic review
Jensen, A. G., Knudsen, S. S., & Bech, B. H. (2022) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2022.107078 · Cited by 17
Schwienteck, K. L., Li, G., Poe, M. M., Cook, J. M., Banks, M. L., & Negus, S. S. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4615-8 · Cited by 17
Vahidifar, M., & Es’haghi, Z. (2022) · Journal of Analytical Chemistry · doi:10.1134/s1061934822050082 · Cited by 16
Valenti, S., Cazorla, C., Romanini, M., Tamarit, J. L., & Macovez, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010196 · Cited by 16
Nitrobenzodiazepines: Postmortem brain and blood reference concentrations
Skov, L. J., Holm, K. M. D., & Línnet, K. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.09.002 · Cited by 16
Effects of Antiepileptic Drug Tapering on Episodic Memory as Measured by Virtual Reality Tests
Höller, Y., Höhn, C., Schwimmbeck, F., Plancher, G., & Trinka, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00093 · Cited by 19
RMD86, a thiophene derivative, promotes antinociceptive and antipyretic activities in mice
da Cruz, R. M. D., Braga, R. M., de Andrade, H. H. N., Monteiro, Á. B., Luna, I. S., da Cruz, R. M. D., Scotti, L., Mendonça, F. J. B., & de Almeida, R. N. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05520 · Cited by 16
Deconstructing tolerance with clobazam
Gidal, B. E., Wechsler, R. T., Sankar, R., Montouris, G., White, H. S., Cloyd, J. C., Kane, M. C., Peng, G., Tworek, D. M., Shen, V., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003253 · Cited by 16
Self-citationPerioperative substitution of anti-epileptic drugs
Wichards, W. S. W., Schobben, A. F. A. M., & Leijten, F. S. S. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7067-z · Cited by 15
Navidpour, L., Shabani, S., Heidari, A., Bashiri, M., Ebrahim‐Habibi, A., Shahhosseini, S., Shafaroodi, H., Tabatabai, S. A., & Toolabi, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104504 · Cited by 15
Zhang, H., Qi, H.-Z., Mao, J., Zhang, H., Luo, Q.-Q., Hu, M., Shen, C., & Ding, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105722 · Cited by 15
Lu, C., Zhu, X., Feng, Y., Ao, W., Li, J., Gao, Z., Luo, H., Chen, M., Cai, F., Zhan, S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01982-8 · Cited by 15
Patel, V., Cordato, D. J., Malkan, A., & Beran, R. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.10.027 · Cited by 15
ADVERSE EFFECTS OF ANTIEPILEPTIC DRUGS
Kovaleva, I. Y. (2017) · Epilepsy and Paroxysmal Conditions · doi:10.17749/2077-8333.2017.9.1.051-061 · Cited by 15
Paronikyan, E. G., Petrou, A., Fesatidou, M., Geronikaki, A. A., Dashyan, S. S., Mamyan, S. S., Paronikyan, R. G., Nazaryan, I. M., & Hakopyan, H. H. (2019) · MedChemComm · doi:10.1039/c9md00187e · Cited by 15
Nair, D. K., Sivanandan, S. T., Kendrekar, P. S., & Namboothiri, I. N. N. (2019) · Tetrahedron · doi:10.1016/j.tet.2019.130761 · Cited by 15
Starting a new anti‐seizure medication in drug‐resistant epilepsy: Add‐on or substitute?
Janmohamed, M., Lawn, N. D., Spilsbury, K., Chan, J., & Dunne, J. W. (2020) · Epilepsia · doi:10.1111/epi.16765 · Cited by 15
Oruch, R., Hodneland, E., Pryme, I. F., & Holmsen, H. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0018-6 · Cited by 15
Liddiard, G. T., Suryavanshi, P. S., & Glykys, J. C. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1342-23.2023 · Cited by 14
Wang, M., Qiao, Y., Luo, Z., Guo, E., Ma, W., Wang, K., Guo, A., & Lian, K. (2024) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2024.106000 · Cited by 14
Durisic, N., Keramidas, A., Dixon, C. L., & Lynch, J. W. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00089 · Cited by 14
Expression and purification of a functional heteromeric GABAA receptor for structural studies
Claxton, D. P., & Gouaux, E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201210 · Cited by 15
Rašković, A., Kvrgić, M. P., Tomás, A., Stilinović, N., Čabarkapa, V., Stojšić‐Milosavljević, A., Kusturica, M. P., & Rakić, D. B. (2020) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902020000318819 · Cited by 14
Wimmer, L., Schönbauer, D., Pakfeifer, P., Schöffmann, A., Khom, S., Hering, S., & Mihovilovič, M. D. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02242d · Cited by 14
11-R-dibenzo[b,e][1,4]diazepin-1-ones, the chemosensors for transition metal cations
Евгеньевич, Т. И., Валерьевна, М. Н., Bumber, A. A., Шепеленко, Е. Н., Revinsky, U. V., Dubonosov, A. D., Александрович, Б. В., & Minkin, V. I. (2012) · Russian Journal of General Chemistry · doi:10.1134/s1070363212070109 · Cited by 14
Update on pharmacotherapy of myoclonic seizures
Striano, P., & Belcastro, V. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1280459 · Cited by 14
Mielcarek, J., Nowak, D. M., Pajzderska, A., Peplińska, B., & Wąsicki, J. W. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.044 · Cited by 14
Masram, L. B., Salim, S. S., Gadkari, Y. U., Bhadke, P. K., & Telvekar, V. N. (2022) · Synthetic Communications · doi:10.1080/00397911.2022.2129389 · Cited by 13
Application of ensemble learning for predicting GABAA receptor agonists
Fu, X., Ding, X., Shi, Y., Wang, D., Wang, Y., Cui, C., Zhu, T., Chen, K., Xiang, P., & Luo, X. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.107958 · Cited by 14
A review of cell-type specific circuit mechanisms underlying epilepsy
Zhao, P., Ding, X., Li, L., & Jiang, G. (2024) · Acta Epileptologica · doi:10.1186/s42494-024-00159-2 · Cited by 13
Cascino, G. D., Tarquinio, D. C., Wheless, J. W., Hogan, R. E., Sperling, M. R., Liow, K. K., Desai, J. D., Davis, C. S., Rabinowicz, A. L., & Carrazana, E. J. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107983 · Cited by 13
Dixon, R. B., Mbeunkui, F., & Wiegel, J. V. (2015) · Journal of Analytical Science & Technology · doi:10.1186/s40543-015-0057-2 · Cited by 13
Isoliquiritigenin, a Chalcone Compound, Enhances Spontaneous Inhibitory Postsynaptic Response
Woo, J., Cho, S., & Lee, C. J. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.2.163 · Cited by 13
Kobayashi, Y., Takemoto, H., Fu, Z., Shimizu, E., & Kinjo, Y. (2016) · Natural Product Communications · doi:10.1177/1934578x1601100836 · Cited by 13
Zhou, L., Wang, M., Wang, K., Wen, T., & Wang, L. (2020) · Applied Organometallic Chemistry · doi:10.1002/aoc.5707 · Cited by 13
Metadata
- Authors
- Riss, J., Cloyd, J., Gates, J., & Collins, S.
- Affiliations
- University of Minnesota (US)
- Minnesota Epilepsy Group (US)
- Corresponding author
- Cloyd, J.
- ORCID
- Cloyd, J.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Wiley
- Published
- 2008-08
- Volume
- 118
- Issue
- 2
- Pages
- 69-86
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W2047978949
- Cited by
- 511
- References
- 205
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 30 · 2023: 26 · 2022: 25 · 2021: 26 · 2020: 40 · 2019: 36 · 2018: 33 · 2017: 25 · 2016: 37 · 2015: 30 · 2014: 39 · 2013: 23 · 2012: 38
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Acta Neurologica Scandinavica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- benzodiazepines, epilepsy, pharmacokinetics, pharmacology, clorazepate, clonazepam, diazepam, lorazepam, midazolam, clobazam, drug tolerance, drug interactions, sedation, cognitive impairment, status epilepticus, febrile seizures, alcohol withdrawal seizures
- MeSH terms
- Benzodiazepines, Epilepsy, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
